

# Chris R Triggles

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11141702/publications.pdf>

Version: 2024-02-01

56  
papers

4,488  
citations

136950

32  
h-index

168389

53  
g-index

57  
all docs

57  
docs citations

57  
times ranked

5954  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. <i>Medical Principles and Practice</i> , 2015, 24, 401-415.	2.4	1,060
2	FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk Between Liver and Brain During Prolonged Fasting. <i>Diabetes</i> , 2014, 63, 4064-4075.	0.6	217
3	Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. <i>British Journal of Pharmacology</i> , 2014, 171, 523-535.	5.4	193
4	The endothelium: influencing vascular smooth muscle in many ways. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 713-738.	1.4	188
5	Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db) mice: role of decreased tetrahydrobiopterin bioavailability. <i>British Journal of Pharmacology</i> , 2002, 136, 255-263.	5.4	164
6	Endothelium-derived relaxing factors: A focus on endothelium-derived hyperpolarizing factor(s). <i>Canadian Journal of Physiology and Pharmacology</i> , 2001, 79, 443-470.	1.4	146
7	2-Furoyl-LIGRLO-amide: A Potent and Selective Proteinase-Activated Receptor 2 Agonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 1124-1131.	2.5	128
8	Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues. <i>Cell Reports</i> , 2019, 26, 2738-2752.e4.	6.4	115
9	A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. <i>British Journal of Pharmacology</i> , 2009, 157, 540-550.	5.4	110
10	A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan. <i>Frontiers in Endocrinology</i> , 2021, 12, 718942.	3.5	107
11	Endothelial Dysfunction in Diabetes Mellitus: Possible Involvement of Endoplasmic Reticulum Stress?. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-14.	3.8	98
12	Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. <i>Vascular Health and Risk Management</i> , 2005, 1, 55-71.	2.3	95
13	Metformin: Is it a drug for all reasons and diseases?. <i>Metabolism: Clinical and Experimental</i> , 2022, 133, 155223.	3.4	92
14	Role of NO in vascular smooth muscle and cardiac muscle function. <i>Trends in Pharmacological Sciences</i> , 1994, 15, 255-259.	8.7	90
15	The Endothelium in Health and Disease-A Target for Therapeutic Intervention.. <i>Journal of Smooth Muscle Research</i> , 2003, 39, 249-267.	1.2	90
16	Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. <i>Journal of Cellular Physiology</i> , 2007, 212, 682-689.	4.1	89
17	Endothelial dysfunction in diabetes: multiple targets for treatment. <i>Pflügers Archiv European Journal of Physiology</i> , 2010, 459, 977-994.	2.8	89
18	Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. <i>British Journal of Pharmacology</i> , 2003, 140, 701-706.	5.4	86

#	ARTICLE	IF	CITATIONS
19	Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. <i>British Journal of Pharmacology</i> , 2005, 144, 953-960.	5.4	84
20	A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. <i>Journal of the American Society of Hypertension</i> , 2010, 4, 102-115.	2.3	84
21	Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. <i>Vascular Pharmacology</i> , 2018, 109, 56-71.	2.1	84
22	Molecular Interplay between microRNA-34a and Sirtuin1 in Hyperglycemia-Mediated Impaired Angiogenesis in Endothelial Cells: Effects of Metformin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 314-323.	2.5	78
23	Multiple mechanisms of vascular smooth muscle relaxation by the activation of Proteinase-Activated Receptor 2 in mouse mesenteric arterioles. <i>British Journal of Pharmacology</i> , 2002, 135, 155-169.	5.4	76
24	Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. <i>Canadian Journal of Physiology and Pharmacology</i> , 2003, 81, 1013-1028.	1.4	76
25	Catalase has negligible inhibitory effects on endothelium-dependent relaxations in mouse isolated aorta and small mesenteric artery. <i>British Journal of Pharmacology</i> , 2003, 140, 1193-1200.	5.4	63
26	Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. <i>Biomolecules</i> , 2019, 9, 846.	4.0	60
27	Cardiovascular impact of drugs used in the treatment of diabetes. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 245-268.	2.5	54
28	Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice. <i>European Journal of Pharmacology</i> , 2006, 551, 98-107.	3.5	48
29	Endothelium-Derived Hyperpolarizing Factor: Is There A Novel Chemical Mediator?. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2002, 29, 153-160.	1.9	42
30	Metformin improves endothelial function in aortic tissue and microvascular endothelial cells subjected to diabetic hyperglycaemic conditions. <i>Biochemical Pharmacology</i> , 2015, 98, 412-421.	4.4	40
31	Proteinase-Activated Receptor-2 (PAR2): Vascular Effects of a PAR2-Derived Activating Peptide via a Receptor Different than PAR2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 985-992.	2.5	36
32	Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 415-430.	1.4	36
33	Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2. <i>Canadian Journal of Physiology and Pharmacology</i> , 2004, 82, 1103-1112.	1.4	35
34	Metformin represses glucose starvation induced autophagic response in microvascular endothelial cells and promotes cell death. <i>Biochemical Pharmacology</i> , 2017, 132, 118-132.	4.4	34
35	Effects of a Western diet versus high glucose on endothelium-dependent relaxation in murine micro- and macro-vasculature. <i>European Journal of Pharmacology</i> , 2008, 601, 111-117.	3.5	31
36	MicroRNA Signature and Cardiovascular Dysfunction. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 419-429.	1.9	31

#	ARTICLE	IF	CITATIONS
37	A photosensitive vascular smooth muscle store of nitric oxide in mouse aorta: no dependence on expression of endothelial nitric oxide synthase. <i>British Journal of Pharmacology</i> , 2003, 138, 932-940.	5.4	28
38	The endothelium in health and disease: A discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes. <i>Molecular and Cellular Biochemistry</i> , 2004, 263, 21-27.	3.1	27
39	NO and the vasculature: where does it come from and what does it do?. <i>Heart Failure Reviews</i> , 2002, 7, 423-445.	3.9	26
40	Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes?. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005, 83, 681-700.	1.4	26
41	The endothelium in compliance and resistance vessels. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 730-744.	2.1	25
42	Nitrosothiol stores in vascular tissue: Modulation by ultraviolet light, acetylcholine and ionomycin. <i>European Journal of Pharmacology</i> , 2007, 560, 183-192.	3.5	24
43	Vascular dysfunction in type 2 diabetic TallyHo mice: role for an increase in the contribution of PGH2/TxA2 receptor activation and cytochrome p450 products This paper is one of a selection of papers published in this Special Issue, entitled The Cellular and Molecular Basis of Cardiovascular Dysfunction, Dhalla 70th Birthday Tribute.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007, 85, 404-412.	1.4	23
44	Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2019, 43, 510-514.	0.8	23
45	Novel endothelium-derived relaxing factors. <i>Journal of Pharmacological and Toxicological Methods</i> , 2000, 44, 441-452.	0.7	22
46	Treatment with a Combination of Metformin and 2-Deoxyglucose Upregulates Thrombospondin-1 in Microvascular Endothelial Cells: Implications in Anti-Angiogenic Cancer Therapy. <i>Cancers</i> , 2019, 11, 1737.	3.7	21
47	Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 289, H206-H211.	3.2	20
48	The vascular endothelium in diabetes: a practical target for drug treatment?. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 101-117.	3.4	20
49	Metformin Prevents Hyperglycemia-Associated, Oxidative Stress-Induced Vascular Endothelial Dysfunction: Essential Role for the Orphan Nuclear Receptor Human Nuclear Receptor 4A1 (Nur77). <i>Molecular Pharmacology</i> , 2021, 100, 428-455.	2.3	17
50	Endothelial cell dysfunction in type I and II diabetes: The cellular basis for dysfunction. <i>Drug Development Research</i> , 2003, 58, 28-41.	2.9	11
51	A Nonthiazolidinedione Peroxisome Proliferator-Activated Receptor $\beta$ Agonist Reverses Endothelial Dysfunction in Diabetic (db/db-/-) Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 364-370.	2.5	9
52	Impact of currently used anti-diabetic drugs on myoendothelial communication. <i>Current Opinion in Pharmacology</i> , 2019, 45, 1-7.	3.5	8
53	Peroxynitrite Biology. , 2014, , 207-242.		6
54	Searching for the physiological role and therapeutic potential of vascular proteinase-activated receptor-2 (PAR2). <i>Drug Development Research</i> , 2003, 60, 14-19.	2.9	2

#	ARTICLE	IF	CITATIONS
55	Desensitization of $\alpha$ -Adrenoceptor Mediated Responses in Vascular Smooth Muscle. , 1996, , 119-138.		0
56	Endothelium-Derived Hyperpolarizing Factor(s). Does it Exist and What Role Does it Play in the Regulation of Blood Flow?. Progress in Experimental Cardiology, 2004, , 341-348.	0.0	0